Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
May 14, 2024 07:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell...
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 07, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
April 15, 2024 08:00 ET
|
Viracta Therapeutics, Inc.
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete...
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
April 01, 2024 08:30 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from...
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
February 29, 2024 08:00 ET
|
Viracta Therapeutics, Inc.
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of...
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
January 04, 2024 08:00 ET
|
Viracta Therapeutics, Inc.
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in...
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
December 12, 2023 08:00 ET
|
Viracta Therapeutics, Inc.
First orphan drug designation for Nana-val granted in EBV+ solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE...